Figure 3, The variation over time of the number and frequency of SARS-CoV-2 specific sequences after mRNA vaccine inoculation in hematopoietic stem cell transplant recipients administered with tixagevimab/cilgavimab. (IMAGE)

Kobe University

Figure 3, The variation over time of the number and frequency of SARS-CoV-2 specific sequences after mRNA vaccine inoculation in hematopoietic stem cell transplant recipients administered with tixagevimab/cilgavimab.

Caption

A: Tixagevimab/Cilgavimab was administered to cases after umbilical cord blood transplant and were inoculated with the mRNA vaccine thereafter (yellow arrow). The anti-SARS-CoV-2 antibody titer (black line) transitioned to an extremely high titer value after prophylactic antibody administration, but even then the researchers were able to assess the reactions after vaccine inoculation by assessing SARS-CoV-2 specific sequences (Blue line). B: By availing of the neutralization activity data of antibodies in the database, the research group was able to assess the characteristics of the elevated antibodies after vaccine inoculation. Modified from journal article.

Credit

© 2023 British Society for Haematology and John Wiley & Sons Ltd.

Usage Restrictions

Permission from journal required.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.